<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509404</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00009601</org_study_id>
    <nct_id>NCT01509404</nct_id>
  </id_info>
  <brief_title>Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection</brief_title>
  <official_title>Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the incidence and severity of late Cytomegalovirus
      (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and
      200 days and after 200 days post-transplant in patients treated with valganciclovir per
      package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
      versus valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam
      100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Late CMV Disease</measure>
    <time_frame>after 200 days post-transplant until 2 years post-transplant</time_frame>
    <description>Number of any clinically significant late CMV disease, defined as CMV syndrome or tissue-invasive disease occurring after the first 200 days post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Early CMV Infection</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Cell Mediated Immunity</measure>
    <time_frame>2 years</time_frame>
    <description>Positive CMV quantiferon at last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>6, 12, and 24 months after transplant</time_frame>
    <description>Renal function will be assessed by an estimated creatinine clearance utilizing the abbreviated Modification of Diet in Renal Disease (MDRD) equation at 6, 12, and 24 months after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Cellular and/or Antibody Mediated Rejection</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Opportunistic Infections</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Asymptomatic CMV Viremia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CMV Seroconversions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cytomegalovirus Disease</condition>
  <arm_group>
    <arm_group_label>Valcyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valcyte then Cytogam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valcyte per package insert guidelines for 200 days post transplant</description>
    <arm_group_label>Valcyte</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV hyperimmune globulin</intervention_name>
    <description>100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant</description>
    <arm_group_label>Valcyte then Cytogam</arm_group_label>
    <other_name>Cytogam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
    <arm_group_label>Valcyte then Cytogam</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients â‰¥ 18 years of age.

          2. Male or female patients who CMV seronegative receiving a kidney, pancreas or liver
             from a seropositive donor.

          3. Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within the past 48 hours prior to receiving transplant or study
             inclusion.

          4. The patient has given written informed consent to participate in the study.

        Exclusion Criteria:

          1. Solid organ transplant recipient is CMV seropositive at the time of transplant.

          2. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).

          3. Patient has uncontrolled concomitant infection or any other unstable medical condition
             that could interfere with the study objectives.

          4. Patients with thrombocytopenia (&lt;25,000/mm3 ), with an absolute neutrophil count of &lt;
             1,000/mm3); and/or leucopoenia (&lt; 2,000/mm3), or anemia (hemoglobin &lt; 6 g/dL) prior to
             study inclusion.

          5. Patient is taking or has been taking an investigational drug in the 30 days prior to
             transplant.

          6. Patient has a known hypersensitivity to valganciclovir, tacrolimus, mycophenolate
             mofetil, rabbit anti-thymocyte globulin, CMV hyperimmune globulin, basiliximab or
             corticosteroids.

          7. Patients with severe diarrhea or other gastrointestinal disorders that might interfere
             with their ability to absorb oral medication.

          8. Patient is pregnant or lactating, where pregnancy is defined as the state of a female
             after conception and until the termination of gestation, confirmed by positive human
             Chorionic Gonadotropin (hCG) laboratory test.

          9. Patient has any form of substance abuse, psychiatric disorder or a condition that, in
             the opinion of the investigator, may invalidate communication with the investigator.

         10. Inability to cooperate or communicate with the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <results_first_submitted>February 9, 2018</results_first_submitted>
  <results_first_submitted_qc>September 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2018</results_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>cytomegalovirus</keyword>
  <keyword>transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valcyte</title>
          <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
        </group>
        <group group_id="P2">
          <title>Valcyte Then Cytogam</title>
          <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valcyte - Kidney Transplant</title>
          <description>Subjects who received a kidney transplant and assigned to the Valcyte only Treatment arm.</description>
        </group>
        <group group_id="B2">
          <title>Valcyte Then Cytogam - Kidney Transplant</title>
          <description>Subjects who received a kidney transplant and assigned to the Valcyte then CytogamTreatment arm.</description>
        </group>
        <group group_id="B3">
          <title>Valcyte - Liver Transplant</title>
          <description>Subjects who received a liver transplant and assigned to the Valcyte only Treatment arm.</description>
        </group>
        <group group_id="B4">
          <title>Valcyte Then Cytogam - Liver Transplant</title>
          <description>Subjects who received a liver transplant and assigned to the Valcyte then Cytogam Treatment arm.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="21" upper_limit="71"/>
                    <measurement group_id="B2" value="54" lower_limit="26" upper_limit="69"/>
                    <measurement group_id="B3" value="58" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="B4" value="60" lower_limit="48" upper_limit="61"/>
                    <measurement group_id="B5" value="56" lower_limit="21" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Retransplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="20"/>
                    <measurement group_id="B2" value="88" spread="21"/>
                    <measurement group_id="B3" value="84" spread="13"/>
                    <measurement group_id="B4" value="91" spread="25"/>
                    <measurement group_id="B5" value="84" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-emptive</title>
          <population>Pre-Emptive applies only to kidney transplant patients. Pre-emptive values were obtained by counting the number of patients who were not on dialysis prior to their kidney transplant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Late CMV Disease</title>
        <description>Number of any clinically significant late CMV disease, defined as CMV syndrome or tissue-invasive disease occurring after the first 200 days post transplant</description>
        <time_frame>after 200 days post-transplant until 2 years post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Late CMV Disease</title>
          <description>Number of any clinically significant late CMV disease, defined as CMV syndrome or tissue-invasive disease occurring after the first 200 days post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Early CMV Infection</title>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Early CMV Infection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Cell Mediated Immunity</title>
        <description>Positive CMV quantiferon at last follow-up</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Cell Mediated Immunity</title>
          <description>Positive CMV quantiferon at last follow-up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function</title>
        <description>Renal function will be assessed by an estimated creatinine clearance utilizing the abbreviated Modification of Diet in Renal Disease (MDRD) equation at 6, 12, and 24 months after transplant</description>
        <time_frame>6, 12, and 24 months after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function</title>
          <description>Renal function will be assessed by an estimated creatinine clearance utilizing the abbreviated Modification of Diet in Renal Disease (MDRD) equation at 6, 12, and 24 months after transplant</description>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GFR at 180 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="22" upper_limit="123"/>
                    <measurement group_id="O2" value="53" lower_limit="30" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GFR at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="26" upper_limit="171"/>
                    <measurement group_id="O2" value="54" lower_limit="31" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GFR at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="29" upper_limit="143"/>
                    <measurement group_id="O2" value="55" lower_limit="20" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Cellular and/or Antibody Mediated Rejection</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Cellular and/or Antibody Mediated Rejection</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Opportunistic Infections</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Opportunistic Infections</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Asymptomatic CMV Viremia</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Asymptomatic CMV Viremia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CMV Seroconversions</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valcyte</title>
            <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
          </group>
          <group group_id="O2">
            <title>Valcyte Then Cytogam</title>
            <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CMV Seroconversions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Valcyte</title>
          <description>valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
Valganciclovir: Valcyte per package insert guidelines for 200 days post transplant</description>
        </group>
        <group group_id="E2">
          <title>Valcyte Then Cytogam</title>
          <description>valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
CMV hyperimmune globulin: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
Valganciclovir: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BK infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Acute rejection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Fleming</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-0312</phone>
      <email>fleminj@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

